C85
Conditions
Interventions
Group 1: Stratification of treatment intensity into 4 risk groups
R1: Stage I and II, completely resected, 2 courses A, B
R2: Stage I and II, uncompletely resected, Stage III, LDH=100U/L, or/and CNS
Sponsors
Justus-Liebig-Universität Gießen, Universitätsklinikum Gießen, Abteilung Pädiatrische Hämatologie und Onkologie
Eligibility
Sex/Gender
All
Age
0 Years to 18 Years
Inclusion criteria
Inclusion criteria: newly diagnosed mature B-NHL or B-ALL informed consent of patient/guardian start of therapy within recruting period of study treatment in a participating centre of study no participation in a concurrend clinical trial no evidence of pregnancy effective contraception
Exclusion criteria
Exclusion criteria: previous malignancy severe immunondeficiency HIV/AIDS previous organ transplantation preexisting disease prohibiting chemotherapy as per protocol significant cytoreductive pre-treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| probability of event-free survival from diagnosis until one year after diagnosis. Events are: recurrence, secondary malignancies or death from any cause | — |
Secondary
| Measure | Time frame |
|---|---|
| toxicity according to NCI criteria particularly of intensified intrathecal therapy in CNS-positive patients during chemotherapy until one month after chemotherapy | — |
Countries
Austria, Czechia, Germany, Switzerland
Contacts
Public ContactAlfred Reiter
Justus-Liebig-Universität Gießen, Abt. Pädiatrische Hämatologie und Onkologie
Outcome results
None listed